What is the present valuation and projected CAGR of the obstructive laryngitis treatment market?
The obstructive laryngitis treatment market size has grown strongly in recent years. It will grow from $1.95 $ billion in 2024 to $2.07 $ billion in 2025 at a compound annual growth rate (CAGR) of 6.0%. The growth in the historic period can be attributed to rising incidence of conditions such as vocal cord paralysis, increased demand for effective treatment options, rise in respiratory and laryngeal disorders, growth in telemedicine, and rising awareness and use of voice therapy.
The obstructive laryngitis treatment market size is expected to see strong growth in the next few years. It will grow to $2.57 $ billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing the need for treatment options, growing incidences of bacterial and viral infections, growing aging population, rising exposure to harmful chemicals, and rising healthcare expenditure. Major trends in the forecast period include technological advancements, integration of telemedicine, biologic therapies, diagnostic imaging, and machine learning.
Get Your Free Sample of The Global Obstructive Laryngitis Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19621&type=smp
What key drivers have fueled the obstructive laryngitis treatment market’s development over the years?
The growing incidences of bacterial and viral infections are expected to propel the growth of the obstructive laryngitis treatment market going forward. Bacterial and viral infections are caused by microorganisms called bacteria and viruses, which invade the body, reproduce, and disturb normal bodily activities. The growing incidence of bacterial and viral infections can be attributed to several factors, including increased global travel, climate change, and antibiotic resistance. Obstructive laryngitis treatment involves antibiotics and corticosteroids to eliminate pathogens and reduce inflammation, while viral infections are managed with symptomatic treatments, corticosteroids for severe inflammation, and supportive care such as voice rest and hydration. For instance, in November 2023, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, around 10.6 million cases of tuberculosis (TB) are predicted to occur globally in 2022, affecting 5.8 million men, 3.5 million women, and 1.3 million children. Therefore, the growing incidences of bacterial and viral infections are driving the obstructive laryngitis treatment market.
What is the segmentation for the obstructive laryngitis treatment market?
The obstructive laryngitis treatmentmarket covered in this report is segmented –
1) By Medication: Glucocorticoid, Dexamethasone, Epinephrine
2) By Route Of Administration: Oral, Intravenous, Other Route Of Administration
3) By Drug Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
Subsegments:
1) By Glucocorticoid: Hydrocortisone, Prednisone, Methylprednisolone, Triamcinolone, Betamethasone, Budesonide,
2) By Dexamethasone: Dexamethasone Sodium Phosphate, Dexamethasone Oral Solution, Dexamethasone Injectable, Dexamethasone Tablets,
3) By Epinephrine: Epinephrine Injection, Epinephrine Autoinjectors, Epinephrine Nebulizer Solution, Epinephrine Inhalation Aerosol
Order your report now for swift delivery
Who are the most influential companies in the obstructive laryngitis treatment market?
Major companies operating in the obstructive laryngitis treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Reckitt Benckiser Group plc, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, Macleods Pharmaceuticals Limited, Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Dr. Reddy’s Laboratories Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Mankind Pharma Limited, Unichem Laboratories Limited, Mylan N.V., Strides Pharma Science Limited, USV Private Limited
What are the top industry trends projected to impact the obstructive laryngitis treatment market?
Major companies operating in the obstructive laryngitis treatment market are focusing on developing innovative solutions, such as chewable tablets, to prevent acid from escaping into the esophagus, alleviating pain and discomfort. A chewable tablet is a solid dosage form of medication designed to be chewed before swallowing, allowing for easier ingestion and faster absorption. For instance, in June 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based manufacturing company, launched the anti-reflux antacid sodium alginate + potassium bicarbonate chewable tablet. The anti-reflux antacid chewable tablet containing sodium alginate and potassium bicarbonate, launched by Akums Drugs and Pharmaceuticals Ltd., is primarily used to treat acid reflux and gastroesophageal reflux disease (GERD). In the context of laryngitis treatment, it may help reduce larynx irritation caused by acid reflux, which can lead to or worsen laryngitis. By forming a protective barrier in the stomach, the tablet prevents acid from rising into the esophagus and throat, alleviating symptoms such as throat irritation and inflammation that can exacerbate laryngitis.
What are the major regional insights for the obstructive laryngitis treatment market, and which region holds the top position?
North America was the largest region in the obstructive laryngitis treatment market in 2024. The regions covered in the obstructive laryngitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Obstructive Laryngitis Treatment Market Report 2025 Offer?
The obstructive laryngitis treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Obstructive laryngitis treatment refers to the medical approaches to address inflammation and obstruction of the larynx (voice box) that impairs breathing and vocal function. It alleviates hoarseness, difficulty breathing, and throat discomfort while reducing inflammation and resolving the obstruction.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19621
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
